Ultragenyx Pharmaceutical (RARE) Inventory Average (2018 - 2026)

Ultragenyx Pharmaceutical (RARE) has 9 years of Inventory Average data on file, last reported at $53.5 million in Q1 2026.

• Quarterly Inventory Average rose 17.54% year-over-year to $53.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.5 million (up 17.54% YoY) and the FY2025 annual result came in at $48.5 million, up 22.83% from the prior year.
• Inventory Average improved to $53.5 million in Q1 2026 per RARE's latest filing, from $52.1 million in the prior quarter.
• Across five years, Inventory Average topped out at $53.5 million in Q1 2026 and bottomed at $17.0 million in Q1 2022.
• The 5-year median for Inventory Average is $34.9 million (2024), against an average of $35.6 million.
• The widest annual swing landed in 2023, when Inventory Average soared 56.82%; it then grew 17.54% in 2026.
• Tracing RARE's Inventory Average over 5 years: stood at $24.3 million in 2022, then surged by 35.29% to $32.9 million in 2023, then soared by 34.31% to $44.2 million in 2024, then climbed by 17.96% to $52.1 million in 2025, then advanced by 2.69% to $53.5 million in 2026.
• Per Business Quant, the three latest RARE Inventory Average figures stand at $53.5 million (Q1 2026), $52.1 million (Q4 2025), and $49.3 million (Q3 2025).

Peer Comparison